Gastrointestinal Health

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.

There may be a pathophysiological basis for therapy relating to the to the gut-liver axis.

Findings from a recent murine model may translate to the human gut microbiome, but assessing chlorine’s effects on the gut microbiome remains complex.

Despite the insignificant differences in efficacy, biomarkers, therapeutic drug level, and ADAs, patients reported a significant number of nocebo effects.

Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial.

No significant demographic or phenotypic differences were found between HLA-DQA1*05 carriers versus non-carriers, in either treatment group.

The approval marks the first major innovation in the United States for the treatment of erosive GERD in over 30 years.

Etrasimod is an advanced synthetic compound classified as a selective modulator of Sphingosine 1-phosphate (S1P) receptors, specifically targeting S1P1, S1P4, and S1P5 receptors .

In a clinical trial, 2 vonoprazan-based regimens demonstrated higher rates of eradication as well as low rates of adverse effects compared to lansoprazole triple therapy.

Mirikizumab-mrkz (Omvoh; Eli Lilly and Company) is the first IL-23p19 antagonist approved for adult patients with moderately to severely active ulcerative colitis.

Infliximab-dyyb (Zymfentra; Celltrion USA) is a subcutaneous treatment for the maintenance treatment of adults with moderately to severely active ulcerative colitis and Crohn disease.

Additional research is needed to further evaluate whether adequate emotional support is linked to improvements in health-related quality of life in adults diagnosed with other cancer.

New innovations are revolutionizing diagnostics and optimizing treatment outcomes, marking significant strides in the fight against digestive diseases.

Social jet lag could create adverse health impacts that a 90-minute difference in the mid-point of sleep can improve.

For many patients with C diff, the experience of medical gaslighting is a common one because many health care providers lack education and familiarity with the disease.

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

Data show these cases pose some of the most significant threats to patients and health systems.

Chronic or recurring episodes can lead to other complications.

As more becomes known about Crohn disease, treatment modalities have evolved with biologic monoclonal antibodies becoming a key part of guideline- and evidence-based medicine.

In a single-center study, investigators reviewed charts of 25 children with inflammatory bowel disease transitioning from infliximab to the biosimilar infliximab-dyyb for maintenance.

In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.

The sleep hormone decreased intestinal homeostasis, which may augment inflammation that causes tissue and intestinal damage.

As patents expire, the development of biosimilars may increase, opening up new opportunities to compare efficacies of these drugs.

Similarities between the symptoms of Clostridioides difficile infection and Crohn disease may cause confusion for health care providers.

The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.

Different guidelines have notable differences between equivalency dosing of proton pump inhibitors (PPI), resulting in confusion and a lack of confidence between medical professionals recommending one PPI over another.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.

Educate patients about the use of nonprescription products for digestive issues, and encourage them to seek further medical care when warrented.

Although antibiotics are an effective treatment option, evidence indicates that fecal microbiota transplant holds promise in treating refractory or recurrent C difficile infections.